ARS Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on ARS Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how ARS Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with ARS Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
ARS Pharmaceuticals Inc (ARS Pharma) is a biopharmaceutical company. Its activities include the development and commercialization of innovative needle-free products for the administration of therapies. The company's product is neffy, a needle-free epinephrine nasal spray designed for emergency treatment of allergic reactions, including anaphylaxis. ARS Pharma's pipeline product includes ARS-2 (Intranasal Epinephrine), for the treatment of acute flares of urticaria. The company's products are primarily used by patients and caregivers in healthcare settings to manage severe allergic reactions. It serves customers across the US. ARS Pharma is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
Suite 300, 11682 El Camino Real, San Diego, California, 92130
Website
ars-pharma.com
Telephone
1 858 7719307
No of Employees
158
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SPRY (NASD)
Revenue (2024)
$84.3M
-5.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-2241.8%
(2024 vs 2023)
Market Cap*
$857.0M
Net Profit Margin (2024)
XYZ
-2,365.9%
(2024 vs 2023)
* As of and is in US$
ARS Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline: | neffy |
| neffy: Type I Anaphylaxis | |
| Pipeline: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In November, the company introduced Get neffy on Us. |
| 2025 | Regulatory Approval | In September, the company received approval for neffy (epinephrine nasal spray) 1 mg and 2 mg doses from the Pharmaceuticals and Medical Devices Agency for the emergency treatment of allergic reactions (anaphylaxis) in adults and children. |
| 2025 | Regulatory Approval | In March, the company received approval from the US Food and Drug Administration for neffy 1 mg (epinephrine nasal spray) for the treatment of Type I Allergic Reactions, including anaphylaxis, in children who are aged 4 years and older and weigh 15 to < 30 kilograms (33 to < 66 lb.). |
Competitor Comparison
| Key Parameters | ARS Pharmaceuticals Inc | Viatris Inc | Sandoz Inc | Amneal Pharmaceuticals Inc | Orexo AB |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Sweden |
| City | San Diego | Canonsburg | Princeton | Bridgewater | Uppsala |
| State/Province | California | Pennsylvania | New Jersey | New Jersey | - |
| No. of Employees | 158 | 30,000 | - | 8,500 | 74 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pratik Shah, Ph.D. | Chairman | Executive Board | 2018 | 55 |
| Richard Lowenthal | Chief Executive Officer; Director; President | Executive Board | 2015 | 60 |
| Kathleen D. Scott | Chief Financial Officer | Senior Management | 2022 | 57 |
| Brian T. Dorsey | Chief Operating Officer | Senior Management | 2022 | 56 |
| Alexander A. Fitzpatrick | Chief Legal Officer; Secretary | Senior Management | 2022 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer